Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.

Mark Kirschbaum, MD, Ivana Gojo, MD, Stuart L. Goldberg, MD, Lisa Kujawski, Ehab Atallah, Peter Marks, MD, PhD, Donna Di Gravio, Lisa Pyle, Syed Rizvi, Jean-Pierre J Issa, MD

Blood (2009) 114 (22): 2089.

https://doi.org/10.1182/blood.V114.22.2089.2089

Published: 2009

Journal Articles

Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Mark Kirschbaum, Ivana Gojo, Stuart L Goldberg, Lisa Kujawski, Ehab Atallah, Peter Marks, Jose Garcia- Vargas, Syed Rizvi, Donna Di Gravio, Janet Ahern, Jean-Pierre Issa

Blood (2008) 112 (11): 3651.

https://doi.org/10.1182/blood.V112.11.3651.3651

Published: 2008

Journal Articles

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia

Blood (2006) 107 (9): 3455–3462.

https://doi.org/10.1182/blood-2005-08-3430

Published: 2006

Journal Articles

Left Ventricular Cardiac Function during the Course of a One Year Multicenter Trial of the Safety and Efficacy with ICL670 5–40mg/kg/day and Deferoxamine 20–60 mg/kg/day in Beta-Thalassemia Patients with Transfusional Hemosideosis.

Dorothy A. Kleinert, NP, MPH, Erica Jones, MD, Cristina P. Sison, PhD, Peter Marks, MD, PhD, Patricia J. Giardina, MD

Blood (2005) 106 (11): 3853.

https://doi.org/10.1182/blood.V106.11.3853.3853

Published: 2005

Journal Articles

Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in β-Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial.

Patrick Walter, PhD, Eric Macklin, PhD, John Porter, MD, Patricia Evans, PhD, Tom Coates, MD, Nancy F. Olivieri, MD, Patricia Giardina, MD, Janet Kwiatkowski, MD, Ellis Neufeld, MD, Bruce Ames, PhD, Jaymes Holland, Peter Marks, MD, Elliott Vichinsky, MD, Paul Harmatz, MD

Blood (2005) 106 (11): 3598.

https://doi.org/10.1182/blood.V106.11.3598.3598

Published: 2005

NARROW

Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.

Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia

Left Ventricular Cardiac Function during the Course of a One Year Multicenter Trial of the Safety and Efficacy with ICL670 5–40mg/kg/day and Deferoxamine 20–60 mg/kg/day in Beta-Thalassemia Patients with Transfusional Hemosideosis.

Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in β-Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial.

Email alerts

ASH Publications

American Society of Hematology

Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.

Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia

Left Ventricular Cardiac Function during the Course of a One Year Multicenter Trial of the Safety and Efficacy with ICL670 5–40mg/kg/day and Deferoxamine 20–60 mg/kg/day in Beta-Thalassemia Patients with Transfusional Hemosideosis.

Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in β-Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only